Amylyx Pharmaceuticals vs Wave Life Sciences
AMLX and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMLX and WVE compare
Amylyx Pharmaceuticals is the larger company, worth 5.3 times as much as Wave Life Sciences ($3.3B against $622M).
Wave Life Sciences scores higher on the StockData Score (10 against 7 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMLX | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $622M |
| Share price | $29.86 | $3.15 |
| Change, 1 year | 135% | −56.5% |
| Change, 5 years | 178% | −26.8% |
| Beta (5Y) | 1.15 | 1.30 |
| Employees | 136 | 317 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.8× |
| P/B | 4.4× | 1.5× (better) |
| FCF yield | – | −33.5% |
| Fair value | – | $5.23 |
| Margin of safety | – | 39.7% |
| Growth | ||
| Revenue growth, 5Y average | – | 16.3% |
| Profitability | ||
| Operating margin | – | −321% |
| Net margin | – | −297% |
| FCF margin | – | −294% |
| Return on equity | −30.1% (better) | −80.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 26.81 (better) | 8.38 |
| Altman Z-score | 59.22 (better) | −0.95 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 92.6% |
| Held by insiders | 8.0% | 23.1% |
| Insider net buying, 12 months | −$10.0M | $66.5M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 12.5% | 13.6% |
Go deeper
- AMLX stock overview
- AMLX income statement
- AMLX valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.